.jpg)
1.9 kgs tumour removed from a 17-year-old Male’s chest cavity at Fortis Gurugram
Doctors at Fortis Memorial Research Institute (FMRI) successfully operated and removed 1.9 Kgs tumor from a 17-year-old male patient’s chest cavity. The patient, who had initially consulted the doctor for a typical neck and chest pain, accompanied by fever, underwent a series of comprehensive medical test that led to the diagnosis of a rare form of tumor - Thymolipoma (a condition in which the thymus gland grows in size and covers extensive portions of the chest and lungs). The team of doctors, led by Dr Udgeath Dhir, Director and Head of Cardiothoracic and Vascular Surgery (CTVS), FMRI, managed to successfully operate and remove the rare benign tumor through a complex surgery.
Post admission at Fortis Gurugram, a high-resolution chest CT scan of the patient was conducted by Dr Dhir’s team, revealing a significantly large mass that occupied the majority of the chest cavity. The mass was putting immense pressure on the lungs and heart, as a result the heart and lungs were not functioning in its total capacity. The doctors recognized the urgent need for medical intervention and went ahead with a high-risk surgery to remove the massive tumour.
By making incisions along the sides of lungs, the team of doctors strategically minimized the potential risks associated with accessing and removing the tumor. One of the most critical aspects of the surgery was the administration of anesthesia. The medical team executed this step with meticulous precision, as inducting anesthesia had high risk factors and would have led to compression of the heart and a potential halt in blood circulation once anesthesia was induced.
Talking about the case, Dr. Udgeath Dhir, Director and Head of Cardiothoracic and Vascular Surgery (CTVS), Fortis Memorial Research Institute said, “Thymolipomas are rare tumors composed of fatty tissue and thymic tissues. Thymolipomas, although benign in nature, can grow to considerable size and cause compression of surrounding structures, leading to difficulty in breathing, chest pain, and other discomforts. In this case, the patient's quality of life was significantly impacted due to the size of the tumor. Using advanced imaging techniques and precise surgical planning, we were able to remove the Thymolipoma, while preserving the integrity of the surrounding vital structures. The procedure involved meticulous dissection and careful attention to detail, and we are pleased to report that the patient is recovering well post the surgery. If such cases are not treated on time, the patient may have severe complications such as breathlessness, atrophic diaphragm muscles and reduced lung capacity. In this case, the chances of recurrence are very less as we removed the entire tissue which had the potential of re-growth.”
Mahipal Singh Bhanot, Senior Vice President & Business Head, Fortis Memorial Research Institute said, “Through their unwavering dedication and meticulous precision, the team of doctors under the guidance of Dr. Udgeath Dhir, saved the life of the patient by adopting the correct line of treatment with the help of accurate and timely diagnosis. Thymolipoma is a rare medical condition and needs expertise and precision treatment. Our doctors, executed the procedure with utmost care, ensuring the patient's safety and well-being”
About Fortis Healthcare Limited
Fortis Healthcare Limited – an IHH Healthcare Berhad Company – is a leading integrated healthcare services provider in India. It is one of the largest healthcare organizations in the country with 28 healthcare facilities, 4,500+ operational beds (including O&M facilities) and over 400 diagnostics centers (including JVs). Fortis is present in India, United Arab Emirates (UAE), Nepal & Sri Lanka. The Company is listed on the BSE Ltd and National Stock Exchange (NSE) of India. It draws strength from its partnership with global major and parent company - IHH, to build upon its culture of world-class patient care and superlative clinical excellence. Fortis employs ~23,000 people (including Agilus Diagnostics Limited) who share its vision of becoming the world’s most trusted healthcare network. Fortis offers a full spectrum of integrated healthcare services ranging from clinics to quaternary care facilities and a wide range of ancillary services.
Post admission at Fortis Gurugram, a high-resolution chest CT scan of the patient was conducted by Dr Dhir’s team, revealing a significantly large mass that occupied the majority of the chest cavity. The mass was putting immense pressure on the lungs and heart, as a result the heart and lungs were not functioning in its total capacity. The doctors recognized the urgent need for medical intervention and went ahead with a high-risk surgery to remove the massive tumour.
By making incisions along the sides of lungs, the team of doctors strategically minimized the potential risks associated with accessing and removing the tumor. One of the most critical aspects of the surgery was the administration of anesthesia. The medical team executed this step with meticulous precision, as inducting anesthesia had high risk factors and would have led to compression of the heart and a potential halt in blood circulation once anesthesia was induced.
Talking about the case, Dr. Udgeath Dhir, Director and Head of Cardiothoracic and Vascular Surgery (CTVS), Fortis Memorial Research Institute said, “Thymolipomas are rare tumors composed of fatty tissue and thymic tissues. Thymolipomas, although benign in nature, can grow to considerable size and cause compression of surrounding structures, leading to difficulty in breathing, chest pain, and other discomforts. In this case, the patient's quality of life was significantly impacted due to the size of the tumor. Using advanced imaging techniques and precise surgical planning, we were able to remove the Thymolipoma, while preserving the integrity of the surrounding vital structures. The procedure involved meticulous dissection and careful attention to detail, and we are pleased to report that the patient is recovering well post the surgery. If such cases are not treated on time, the patient may have severe complications such as breathlessness, atrophic diaphragm muscles and reduced lung capacity. In this case, the chances of recurrence are very less as we removed the entire tissue which had the potential of re-growth.”
Mahipal Singh Bhanot, Senior Vice President & Business Head, Fortis Memorial Research Institute said, “Through their unwavering dedication and meticulous precision, the team of doctors under the guidance of Dr. Udgeath Dhir, saved the life of the patient by adopting the correct line of treatment with the help of accurate and timely diagnosis. Thymolipoma is a rare medical condition and needs expertise and precision treatment. Our doctors, executed the procedure with utmost care, ensuring the patient's safety and well-being”
About Fortis Healthcare Limited
Fortis Healthcare Limited – an IHH Healthcare Berhad Company – is a leading integrated healthcare services provider in India. It is one of the largest healthcare organizations in the country with 28 healthcare facilities, 4,500+ operational beds (including O&M facilities) and over 400 diagnostics centers (including JVs). Fortis is present in India, United Arab Emirates (UAE), Nepal & Sri Lanka. The Company is listed on the BSE Ltd and National Stock Exchange (NSE) of India. It draws strength from its partnership with global major and parent company - IHH, to build upon its culture of world-class patient care and superlative clinical excellence. Fortis employs ~23,000 people (including Agilus Diagnostics Limited) who share its vision of becoming the world’s most trusted healthcare network. Fortis offers a full spectrum of integrated healthcare services ranging from clinics to quaternary care facilities and a wide range of ancillary services.